Original Research
Accepted on 17 Nov 2025
Cost-Effectiveness Analysis of First-Line Versus Second-Line Use of CDK4/6 Inhibitors Combined With Endocrine Therapy in Advanced HR+/HER2-Breast Cancer in China: Based on the SONIA Trial
in Drugs Outcomes Research and Policies